196 related articles for article (PubMed ID: 25158386)
1. [Treatment of post-menopausic osteoporosis: what's new in 2014?].
Reginster JY; Neuprez A; Lecart MP; Sarlet N; Distèche S; Bruyère O
Rev Med Liege; 2014; 69(7-8):441-53. PubMed ID: 25158386
[TBL] [Abstract][Full Text] [Related]
2. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
3. Current options for the management of postmenopausal osteoporosis.
Lecart MP; Reginster JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2533-52. PubMed ID: 21916810
[TBL] [Abstract][Full Text] [Related]
4. New developments in the treatment of osteoporosis.
Eriksen EF; Halse J; Moen MH
Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
[TBL] [Abstract][Full Text] [Related]
5. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
[TBL] [Abstract][Full Text] [Related]
6. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
7. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
8. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
Silverman SL; Komm BS; Mirkin S
Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
Pinkerton JV; Thomas S; Dalkin AC
Clin Obstet Gynecol; 2013 Dec; 56(4):711-21. PubMed ID: 24100598
[TBL] [Abstract][Full Text] [Related]
10. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of postmenopausal osteoporosis in 2004].
Reginster JY; Devogelaer JP
Rev Med Liege; 2004 Nov; 59(11):633-47. PubMed ID: 15646737
[TBL] [Abstract][Full Text] [Related]
13. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporosis].
Buck G; Perger L; Bischoff-Ferrari HA
Praxis (Bern 1994); 2011 Jul; 100(14):821-32. PubMed ID: 21732293
[No Abstract] [Full Text] [Related]
15. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
16. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract][Full Text] [Related]
17. [Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy].
Takeuchi Y
Clin Calcium; 2012 Jun; 22(6):897-903. PubMed ID: 22653031
[TBL] [Abstract][Full Text] [Related]
18. New management options for osteoporosis with emphasis on SERMs.
McClung MR
Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Eastell R; Rosen CJ; Black DM; Cheung AM; Murad MH; Shoback D
J Clin Endocrinol Metab; 2019 May; 104(5):1595-1622. PubMed ID: 30907953
[TBL] [Abstract][Full Text] [Related]
20. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]